Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)

被引：0
|
作者：
Navarro Martin, M. [1 ]
Teran Brage, E. [1 ]
Campana-Diaz, E. [2 ]
Garcia-Talavera, P. [2 ]
Reguera Puertas, P. [1 ]
Rama-Alonso, S. [2 ]
Garijo-Martinez, M. C. [1 ]
Felix, L. C. [1 ]
Diaz Sanchez, P. [1 ]
Vidal Tocino, R. [1 ]
Fonseca Sanchez, E. [1 ]
机构：
[1] Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Univ Hosp Salamanca, Dept Nucl Med, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219P
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [1] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [2] 177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting
    Sassic, Jessica
    Farasat, Sadaf
    Hermel, David
    Sigal, Darren
    Xavier, Marin Feldman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [4] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [5] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [6] 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: A real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center.
    Nalder, Mark
    Ladwa, Rahul
    Raina, Anant
    Burge, Matthew E.
    Love, Amanda
    Pattison, David A.
    Ramsay, Stuart
    Wyld, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, U. M. M.
    Ilan, E.
    Sandstrom, M.
    Bamerny, M.
    Garske-Roman, U.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
  • [8] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [9] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [10] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
12345